Change in the following biomarkers: inflammatory/immune markers uPAR, PAI-1, ULBP2, B7-H1, MIF, TGF-β; and PSA compared to placebo. 12 months [clinicaltrials_resource:cea2ee1d23ce0bacaeb1670b184e31f6]
All assessments are as per standard of care. The only additional intervention is a 5 mL peripheral vein phlebotomy at each visit. Patients will be followed at 3, 6, 9 and 12 months after initiation of the trial. Clinic visits will assess side effects of drug and include routine follow-up for prostate cancer management. Serum samples for the above-described makers of immune activity will be obtained at the month 3, 6, 9 and 12 visit.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Change in the following biomarkers: inflammatory/immune markers uPAR, PAI-1, ULBP2, B7-H1, MIF, TGF-β; and PSA compared to placebo. 12 months [clinicaltrials_resource:cea2ee1d23ce0bacaeb1670b184e31f6]
All assessments are as per standard of care. The only additional intervention is a 5 mL peripheral vein phlebotomy at each visit. Patients will be followed at 3, 6, 9 and 12 months after initiation of the trial. Clinic visits will assess side effects of drug and include routine follow-up for prostate cancer management. Serum samples for the above-described makers of immune activity will be obtained at the month 3, 6, 9 and 12 visit.
Bio2RDF identifier
cea2ee1d23ce0bacaeb1670b184e31f6
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:cea2ee1d23ce0bacaeb1670b184e31f6
measure [clinicaltrials_vocabulary:measure]
Change in the following biomar ...... ; and PSA compared to placebo.
time frame [clinicaltrials_vocabulary:time-frame]
description
All assessments are as per sta ...... he month 3, 6, 9 and 12 visit.
identifier
clinicaltrials_resource:cea2ee1d23ce0bacaeb1670b184e31f6
title
Change in the following biomar ...... compared to placebo. 12 months
@en
type
label
Change in the following biomar ...... 2ee1d23ce0bacaeb1670b184e31f6]
@en